The world's first live sperm analyzer has been launched! The Basecare Medical-B (2170. HK) intelligent sperm analyzer is expected to replace the traditional CASA diagnostic mode!

SUZHOU, China, Nov. 4, 2024 /PRNewswire/ -- According to the latest data from the Maternal and Child Health Department of the Chinese National Health Commission, there are currently 602 medical institutions in China that have been approved to carry out human assisted reproductive technology, and the number of IVF institutions worldwide is also continuously increasing. These institutions mainly use computer-aided sperm analysis (CASA) methods to analyze indicators such as sperm quantity, vitality, and morphology in sperm testing, in accordance with the WHO Fifth Edition guidelines. From the demand side, the decline in sperm quality among Chinese men has become an undeniable fact. The Frost Sullivan report points out that in the past 40 years, the sperm count of Chinese men has decreased by as much as 75%, and the proportion of infertility caused by male factors is close to 40%.

According to data from China Intelligent Research Consulting, the market size of sperm quality analyzers in China will continue to expand in the coming years. In 2023, its scale has approached 300 million RMB, and the global market size of sperm analyzers is as high as 400 million US dollars. What is even more worth looking forward to is that if developed at a compound growth rate of 10%, the global market size will exceed 500 million US dollars by 2026. This is a market with enormous potential, like a gold mine waiting to be excavated, full of opportunities.

In addition, in the application of traditional CASA technology, patients have to travel to and from the hospital at least twice, and sometimes even wait for a week to receive the test report. In contrast, Basecare Medical's intelligent sperm quality analyzer uses AI technology for analysis, without the need for staining sperm samples, and can complete the analysis of the morphology, concentration, and vitality of unstained live sperm within 3 minutes at the fastest. Patients only need to undergo one test to identify qualified sperm that can be used for embryo culture, greatly optimizing their service experience. By reducing the number of tests and shortening waiting times, the Basecare sperm analyzer not only improves patient satisfaction, but also significantly enhances hospital efficiency and shortens the overall duration of IVF cycles.

Basecare Medical Intelligent Sperm Analyzer (NMPA number: 20242222101)